Exploration of structural divesisty of secondary metabolites in unstudied microbial species

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K07719
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Bioorganic chemistry
• Research Institution: Toyama Prefectural University
• Principal Investigator: IGARASHI YASUHIRO 富山県立大学, 工学部, 教授 (20285159)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 天然物 / 微生物 / 創薬

Outline of Final Research Achievements

Exhaustive chemical screening was carried out from unstudied or under-evaluated microbial species in order to obtain structurally novel compounds for drug discovery. One new cyclopentenone derivative, three furanone-containing polyketides, and two new anthraquinone derivatives were found from a thermophilic Firmicutes bacterium Thermosporothrix, thermophilic Actionobacteria Sphaerimonospora and Actinomadura, respectively. In addition, a new a-pyrone and furan derivatives, a bicyclic polyketide, and three cyclic peptides were isolated from rare fungi of the genus Robillarda, Phacidiopicnys, and Cladobotryum, respectively, all of which belong to the phylum Ascomycetes. Each new compound possesses the structural uniqueness and novelty and biological properties such as adipocyte differentiation inducing activity, inhibitory activity of tumor cell invasion, and autophagy-inducing activity.

Free Research Field

天然物化学

Academic Significance and Societal Importance of the Research Achievements

微生物の生産する化合物からは抗生物質，抗癌剤，代謝異常の治療薬などさまざまな医薬品が実用化され，人類の福祉に役立てられてきた。一方で，地球上の全微生物のうち，90％の微生物が未研究の新種と推定されている。そのような未知微生物は新薬候補化合物を生産する能力を有すると考えられるため，未研究微生物が生産する新規化合物の構造や活性の解明を通じて，それらの化合物を医薬探索研究に資することは，新薬開発に寄与するものと期待される。